Hyperfine Initiates Clinical Study to Expand Portable MRI Capabilities with Contrast Enhancement

Hyperfine查看公司主页, Inc. has enrolled the first patient in the Contrast PMR study, a prospective, multi-center clinical trial designed to evaluate the feasibility and visualization benefits of contrast-enhanced ultra-low-field portable MRI. The study aims to support a future FDA 510(k) submission to expand the Swoop® system's intended use to include gadolinium-based contrast agents.

Study Design and Objectives

The primary objective of the Contrast PMR study is to evaluate the visualization of brain lesions, including lesions associated with blood-brain barrier disruption, using contrast agents with ultra-low-field portable MRI. Visualization benefits will be assessed using three endpoints related to lesion appearance. The study will enroll approximately 70 patients across multiple sites in the United States.

"Portable MRI has already changed how and where we image the brain at our center, and incorporating the use of contrast is a natural next step," said Mark Anderson, MD, Chief Medical Officer at the CHRISTUS Mother Frances Hospital (搜索)搜索该词条 study site. "Contrast-enhanced MRI is important for evaluating many neurological conditions, and we are looking forward to participating in this study to assess contrast-enhanced imaging with the Swoop® system."

Clinical Applications and Timeline

The ability to use gadolinium-based contrast agents could enhance the Swoop® system's clinical utility, particularly in cases where contrast is commonly used, such as brain tumors, suspected abscesses, and inflammatory conditions like multiple sclerosis. Tom Teisseyre, PhD, Chief Operating Officer at Hyperfine查看公司主页, noted that the company anticipates submission to the FDA for indication expansion towards the end of 2026.

"Seeing contrast at ultra-low field strengths is an exciting expansion opportunity for the utility of the Swoop® system," Teisseyre explained. "The ability to use gadolinium-based contrast agents could enhance its clinical utility, particularly in cases where contrast is commonly used."

Recent Technological Advances

This clinical initiative follows recent regulatory and clinical milestones for Hyperfine查看公司主页. The company recently received FDA clearance for the first Optive AI™ software update with advanced diffusion imaging capability, specifically focused on enhancing stroke detection with the Swoop® system. Additionally, Hyperfine announced the publication of breakthrough clinical data demonstrating the system's stroke detection capabilities.

"Stroke detection represents a critical driver of the Swoop® system's expansion into emergency departments," commented Maria Sainz, President and CEO of Hyperfine查看公司主页. "The results from our next-generation Swoop® system, combined with our new, advanced multi-direction DWI sequence that was recently cleared by the FDA, are truly remarkable."

Technology Platform

The Swoop® Portable MR Imaging® Systems are FDA-cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices designed for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.

Hyperfine查看公司主页 describes itself as the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The company was founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer (搜索)搜索该词条.